Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
The Rafah border crossing, Gaza's sole gateway to Egypt, has partially reopened for pedestrian traffic after a prolonged Israeli closure, offering a fragile hope for medical evacuations and family reunifications.
A coalition of major international NGOs is refusing to comply with Israeli orders to hand over detailed staff information, calling it a safety risk and an obstruction of aid, as tensions escalate following the expulsion of Médecins Sans Frontières.
Kuwait mandates sweeping regulations on food delivery platforms, capping commissions and banning exclusivity deals after uncovering anti-competitive practices that hurt restaurants and consumers.
A wave of commercial flight disruptions is pushing a new class of travelers toward private aviation, not for opulence but for reliability. We examine the shifting calculus of air travel and what a seat actually costs.
Energy Transfer LP announced a significant increase to its quarterly distribution alongside a multi-billion dollar capital expenditure plan for new pipeline and infrastructure projects, signaling confidence in its cash flow stability and long-term growth prospects.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
Despite a 25% drop in earnings per share, Coronation Fund Managers (JSE:CML) delivered a robust 57% total shareholder return over the past year, driven by revenue growth and strong market sentiment, outperforming the broader South African market.
The Rafah border crossing between Gaza and Egypt reopened for pedestrian traffic Monday, ending a near two-year shutdown. The vital gateway, crucial for aid and movement, resumes under a complex new security framework involving Israeli oversight and international monitors.
Israeli authorities have issued expulsion orders to a Bedouin community near Ramallah, while settler attacks on schools and homes intensify across the occupied West Bank, further constricting Palestinian living space.
